Multiple Myeloma: International Myeloma Foundation : •treatment options : clinical trials : Myeloma Matrix

Clinical Trials

share |

Myeloma Matrix

expand all

collapse all

FDA Approved

	COMPANY	INDICATION
Adriamycin®, Rubex® doxorubicin Adriamycin®, Rubex® doxorubicin	Pfizer, Bristol-Myers Squibb	Used as primary induction thereapy in combination with Velcade and dexamethasone (PAD) or with vincristine and dexamethasone (VAD). May be used with cyclophosphamide, vincristine, and dexamethasone (C-VAD) or with dexamethasone, thalidomide, cisplatin, and cyclophosphamide as salvage therapy (DT-PACE).
Alkeran® melphalan Alkeran® melphalan	Celgene Corporation	For transplant patients, used as high-dose therapy with stem cell rescue; for non-transplant patients, used as frontline therapy in combination with prednisone plus or minus another drug; may also be used as salvage therapy.
Aredia® pamidronate, pamidronic acid Aredia® pamidronate, pamidronic acid	Novartis	Administered monthly as an intravenous infusion lasting 2-4 hours for the prevention of bone disease in myeloma.
Cytoxan®, Neosar®, Procytox® cyclophosphamide Cytoxan®, Neosar®, Procytox® cyclophosphamide	Cyclophosphamide Tablets (Roxane Laboratories Inc-Boehringer Ingelheim), Cytoxan® ( Bristol-Myers Squibb Co - Mead Johnson and Co), Neosar® (Pfizer - Pharmacia & Upjohn)	Used in frontline treatment with Velcade and dexamethasone; used in salvage therapy as monotherapy, with Velcade and dex, len and dex, and as part of DCEP, DT-PACE, and C-VAD.
Decadron dexamethasone Decadron dexamethasone	off patent--many manufacturers	Used throughout treatment course of myeloma, both as monotherapy and in combination with other drugs.
DOXIL® doxorubicin liposome HCI injection DOXIL® doxorubicin liposome HCI injection	off patent	In combination with bortezomib for patients who have not previously received bortezomib and have received at least one prior therapy.
Eposin®, Etopophos®, Vepesid®, VP-16®, etoposide Eposin®, Etopophos®, Vepesid®, VP-16®, etoposide	off patent--many manufacturers	Used in salvage therapy for myeloma in combination with dexamethasone, cyclophosphamide, and cisplatin; and in combination with dexamethasone, thalidomide, cisplatin, doxorubicin, and cyclophosphamide.
KYPROLIS® carfilzomib KYPROLIS® carfilzomib	Onyx Pharmaceuticals	For the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within sixty days of the completion of the last therapy.
Mozobil® plerixafor AMD 3100 Mozobil® plerixafor AMD 3100	Genzyme	Stem cell mobilizer used with G-CSF prior to transplant.
Platin® cisplatin, cisplatinum Platin® cisplatin, cisplatinum	Cadila Healthcare	Salvage therapy for myeloma used in combination with dexamethasone, cyclophosphamide, and etoposide (DCEP) and with dexamethasone, thalidomide, doxorubicin, cyclophosphamide, and etoposide (DT-PACE).
POMALYST® pomalidomide CC-4047 POMALYST® pomalidomide CC-4047	Celgene Corporation	Indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of last therapy.
Revlimid® lenalidomide CC-5013 Revlimid® lenalidomide CC-5013	Celgene Corporation	Numerous studies of Revlimid in various combinations or as a single agent .
Thalomid® thalidomide Thalomid® thalidomide	Celgene Corporation	Indicated for the treatment of patients with newly diagnosed multiple myeloma
VELCADE® bortezomib PS-341 VELCADE® bortezomib PS-341	Millennium: The Takeda Oncology Company	In June 2008, VELCADE's approval was expanded to include not only relapsed/refractory disease, but previously untreated myeloma patients. On January 23, 2012, the FDA approved subcutaneous administration of Velcade in all approved indications.
Zometa® zoledronate, zoledronic acid Zometa® zoledronate, zoledronic acid	Novartis	Given monthly as an IV infusion for the prevention of bone loss in myeloma. Also helps reduce serum calcium levels.

Phase III

	COMPANY	INDICATION
Aplidin® plitidepsin Aplidin® plitidepsin	PharmaMar, SA	Randomized, multi-center, open-label study in combination with dexamethasone vs. dexamethasone alone in patients with rel/ref MM. Active trial no longer accruing patients.
elotuzumab HuLuc63 elotuzumab HuLuc63	Bristol-Myers Squibb	Rev/dex with or without elotuzumab in the treatment of newly diagnosed MM (ELOQUENT 1); Rev/dex with or without elotuzumab in the treatment of relapsed/refractory MM (ELOQUENT 2).
Ethyol® amifostine Ethyol® amifostine	MedImmune, Inc.	Cytoprotective agent to allow higher-dose therapy with auto-transplant.
ExAblate® MRI-guided focused ultrasound surgery ExAblate® MRI-guided focused ultrasound surgery	InSightec Inc.	Study comparing the safety and effectiveness of magnetic resonance guided focused ultrasound (MRgFUS) and external beam radiation (EBRT) for treatment of metastatic bone tumors and multiple myeloma. Study completed.
KYPROLIS® carfilzomib PR-171 KYPROLIS® carfilzomib PR-171	Onyx Therapeutics, Inc.	Various phase III trials, including one comparing carfilzomib/dex to bortezomib/dex.
masitinib AB1010 masitinib AB1010	AB Science	Study to evaluate efficacy and safety of masitinib in patients with relapsed or refractory MM. Patients are randomized to receive bortezomib/dex with placebo or bortezomib/dex with masitinib.
MLN9708 MLN9708	Millennium: The Takeda Oncology Company	Oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.
panobinostat LBH589 panobinostat LBH589	Novartis	A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
POMALYST® pomalidomide CC-4047 POMALYST® pomalidomide CC-4047	Celgene Corporation	Studies include single-arm study with low-dose dexamethasone and a randomized study with low- versus high-dose dexamethasone.
Revlimid® lenalidomide CC-5013 Revlimid® lenalidomide CC-5013	Celgene Corporation	Various trials are actively accruing patients, evaluating data, or soon to be opened. Check clinicaltrials.gov for complete listing of phase III lenalidomide trials.
VELCADE® bortezomib PS-341 VELCADE® bortezomib PS-341	Millennium	Various trials in the US, Spain, and the UK for use with transplant, consolidation, induction, and maintenance therapy.
XGEVA(TM) denosumab, osteoprotegerin, OPG AMG 162 XGEVA(TM) denosumab, osteoprotegerin, OPG AMG 162	Amgen	Denosumb compared to zoledronic acid in the treatment of bone disease in patients with multiple myeloma
Zolinza® vorinostat SAHA, MK0683 Zolinza® vorinostat SAHA, MK0683	Merck	Use of thalidomide, lenalidomide, bortezomib and vorinostat in the initial treatment of newly diagnosed MM (Myeloma XI).

Phase II/III

Phase II

Phase I/II

	COMPANY	INDICATION
Actos® pioglitozone Actos® pioglitozone	Takeda	Effect of an anti-inflammatory therapy consisting of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan on patients with relapsed or refractory or progressive MM.
ALT-801 ALT-801	Altor BioScience Corporation	Study of a p53-specific, scTCR/IL-2 fusion protein in patients with relapsed or refractory multiple myeloma.
AR-42 (formerly HDAC-42) AR-42 (formerly HDAC-42)	Arno Therapeutics	Orally available inhibitor of both histone and non-histone deacetylation proteins for patients with advanced or relapsed MM, CLL, or lymphoma
ARRY-520 ARRY-520	Array BioPharma	Novel kinesin spindle protein inhibitor for patients with relapsed or refractory mm or plasma cell leukemia who have already received at least two previous treatments.
ASP7487 (OSI-906) ASP7487 (OSI-906)	Astellas Pharma	ASP7487 in combination with Velcade and dexamethasone in relapsed and refractory MM. Not yet enrolling patients as of 9/24/12.
AT7519M AT7519M	Astex Therapeutics	Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
autologous tumor cell vaccine autologous tumor cell vaccine	Johns-Hopkins, NCI	Randomized Phase II Trial of Dendritic Cell-Based Idiotype Vaccination With Adjuvant Cytokines for Plateau Phase and Post-Transplant Multiple Myeloma
BIW-8962 BIW-8962	BioWa, Incorporated	Dosing study of monoclonal antibody that targets the GM-2 ganglioside (expressed at high levels on the surface of mm cells) followed by efficacy study.
BKT140 (CXCR4) BKT140 (CXCR4)	Biokine Therapeutics	CXCR4 antagonist with stem cell mobilization and antimyeloma effects in first human trial, which is now completed.
brostallicin PNU-166196 brostallicin PNU-166196	Pharmacia and NCI	For the treatment of recurrent or refractory multiple myeloma.
BT062 BT062	Biotest Pharmaceuticals Corporation	Safety and dose-determing study of BT062 in patients with relapsed or refractory multiple myeloma. Also a study of BT062 in combination with len/dex in patients with relapsed/refractory MM.
Busulfex(R) busulfan Busulfex(R) busulfan	Otsuka America Pharmaceutical	For use in auto transplant; various trials
CDX-1401 CDX-1401	Celldex Therapeutics	to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant to patients with advanced cancers that are known to express the NY-ESO-1 protein.
daratumumab HuMax-CD38 (human IgG1,k antibody) daratumumab HuMax-CD38 (human IgG1,k antibody)	Genmab A/S	Studies of an antibody to the CD 38 molecule: one monotherapy; one with Velcade + dexamethasone; one with Revlimid and dexamethasone.
delanzomib CEP-18770 delanzomib CEP-18770	Teva	Oral, boronic acid-based proteasome inhibitor in two studies, one as monotherapy, the other in combination with lenalidomide + dexamethasone, that are no longer accruing patients but are still active.
DKN-01 DKN-01	Dekkun Corporation	Not yet recruiting: DKN-01 and Revlmid/dexamethasone in patients with rel/ref MM.
elotuzumab HuLuc63 elotuzumab HuLuc63	Bristol-Myers Squibb	Bortezomib, dexamethasone, and lenalidomide with or without elotuzumab in treating patients with newly diagnosed high-risk MM.
everolimus RAD001 everolimus RAD001	Novartis	mTOR (mammalian target of Rapamycin) inhibitor for patients with relapsed/refractory mm.
HTert vaccine + autologous T cells HTert vaccine + autologous T cells	University of Pennsylvania, University of Maryland	Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
HuMax®-CD38 daratumumab CD38 mAb HuMax®-CD38 daratumumab CD38 mAb	Genmab	Safety and dose-finding study of a monoclonal antibody to CD38 for the treatment of multiple myeloma.
ImMucin MUC1 peptide vaccine ImMucin MUC1 peptide vaccine	Vaxil Bio Therapeutics, Ltd.	A study to assess the safety and efficacy of MUC1 peptide vaccine and hGM-CSF in patients with MUC1-positive tumor malignancies
Istodax® romidepsin (depsipeptide) FR901228, FK228 Istodax® romidepsin (depsipeptide) FR901228, FK228	Celgene Corporation, Janssen-Cilag	Romidepsin (depsipeptide) and bortezomib in patients with relapsed myeloma.
ixazomib MLN9708 ixazomib MLN9708	Millennium Pharmaceuticals	Several trials recruiting patients with MLN9708 alone or in combination with lenalidomide and dex or melphalan and dex in patients with newly diagnosed MM.
KW-2478 KW-2478	Kyowa Hakko Kirin Pharma	Open-label, dose-escalation, multicenter phase 1/2 study of KW-2478 in combination with bortezomib in subjects with relapsed and/or refractory multiple myeloma. Active, not recruiting further patients.
KYPROLIS® carfilzomib PR-171 KYPROLIS® carfilzomib PR-171	Onyx Pharmaceuticals	Various phase I/II studies of carfilzomib in combination with other drugs.
milatuzumab hLL1 milatuzumab hLL1	Immunomedics	Study of a conjugate of milatuzumab and doxorubicin in patients with myeloma.
MLN8237 MLN8237	Millennium: The Takeda Oncology Company	Aurora kinase inhibitor and bortezomib in treating patients with relapsed or refractory MM.
MOR202, MOR03087 MOR202, MOR03087	MorphoSys AG	Phase I/IIa study of human anti-CD38 antibody in relapsed/refractory MM
Nexavar® sorafenib, sorafenib tosylate BAY 43-9006, NSC-724772 Nexavar® sorafenib, sorafenib tosylate BAY 43-9006, NSC-724772	Bayer and Onyx Pharmaceuticals	A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
noscapine CB3304 noscapine CB3304	Cougar Biotechnology	Oral alkaloid derived from opium; trial for relapsed/refractory mm. STUDY COMPLETED.
obatoclax GX15-070 obatoclax GX15-070	Cephalon	In combination with Velcade for the treatment of relapsed MM. Study ongoing, but no longer recruiting patients.
oprozomib ONX 0912 (formerly PR 047) oprozomib ONX 0912 (formerly PR 047)	Onyx Pharmaceuticals	Multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory MM.
panobinostat LBH589 panobinostat LBH589	Novartis	Oral melphalan combined with panobinostat for patients with relapsed or refractory mm
PAT-SM6 PAT-SM6	Patrys	Safety and preliminary efficacy study of the anti-GRP78 monoclonal antibody PAT-SM6 in patients with relapsed or refractory MM.
POMALYST® pomalidomide CC-5013 POMALYST® pomalidomide CC-5013	Celgene Corporation	A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide
PRLX 93936 PRLX 93936	Prolexys Pharmaceuticals	Safety, efficacy, and pharmacokinetics of a small molecule that targets the RAS protein.
Prochymal™ cultured adult human mesanchymal stem cells Prochymal™ cultured adult human mesanchymal stem cells	Osiris Therpeutics	For treatment of graft-versus-host disease following allo transplant.
PVX-410 PVX-410	OncoPep	Study of a multi-peptide vaccine to treat smoldering myeloma.
rocilinostat ACY-1215 rocilinostat ACY-1215	Acetylon Pharmaceuticals	Trials with oral selective HDAC6 inhibitor in combination with Vel/dex and in combination with Rev/dex for rel/ref MM.
SNS01-T SNS01-T	Senesco Technologies, Inc.	Safety and tolerability study in relapsed/refractory MM.
T cells targeted to MAGE-A3/6 and NY-ESO-1 T cells targeted to MAGE-A3/6 and NY-ESO-1	Adaptimmune	Dual-Cohort, Two-Site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T cells Expressing a High Affinity TCR Specific for MAGE-A3/6 or NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma
TH-302 TH-302	Threshold Pharmaceuticals	Open-label study of TH-302 as monotherapy and in combination with bortezomib in subjects with relapsed/refractory MM.
Torisel™ temsirolimus CCI-779 Torisel™ temsirolimus CCI-779	Wyeth	m-TOR inhibitor in studies in combination with bortezomib (Velcade) or lenalidomide for rel/ref MM.
Treanda® bendamustine Treanda® bendamustine	Cephalon	In combination with Velcade for patients with relapsed/refractory MM.
treosulfan treosulfan	various manufacturers	Effect of anti-inflammatory therapy consisting of lenalidomide in combination with pioglitazone, dexamethasone and alkylating agent treosulfan for patients with relapsed or refractory or progressive multiple myeloma(MM).
VELCADE® bortezomib PS-341, LDP-341, MLN-341 VELCADE® bortezomib PS-341, LDP-341, MLN-341	Millennium: The Takeda Oncology Company	In multiple trials in combination with other agents
Viracept® nelfinavir mesylate Viracept® nelfinavir mesylate	ViiV Healthcare	Nelfinavir and lenalidomide/dexamethasone in patients with progressive MM who have failed lenalidomide-containing therapy.
Zalypsis PM00104 Zalypsis PM00104	PharmaMar (Madrid, Spain)	Marine-derived alkaloid with potent in vivo and in vitro anti-myeloma activity.
Zolinza® vorinostat/SAHA MK0683 Zolinza® vorinostat/SAHA MK0683	Merck	Vorinostat, lenalinomide and dexamethasone in MM refractory to previous lenalinomide-containing regimens (RZD)

Phase I

	COMPANY	INDICATION
4SC-202 4SC-202	Planegg-Martinsried	Dosing, safety, tolerability, and pharmacokinetic study of a selective HDAC inhibitor for hematologic malignancies.
ACE-041 ACE-041	Acceleron	To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma
anti-KIR monoclonal antibody 1-7F9 anti-KIR monoclonal antibody 1-7F9	Novo Nordisk	Safety and tolerability study of an anti-KIR mAb for patients with relapsed/refractory MM. Study completed as of May, 2012.
AP24534 AP24534	Ariad Pharmaceuticals	Maximum tolerated dose of AP24534 in CML and other hematological malignancies.
ARRY-614 ARRY-614	Array BioPharma	Orally active p38/Tie2 inhibitor in dose escalation trial.
Avastin™ bevacizumab, rhuMAb-VEGF Avastin™ bevacizumab, rhuMAb-VEGF	Genentech Inc.	Bevacizumab and bortezomib inpatients with advanced malignancy.
AVN994 AVN994	Avalon Pharmaceuticals	Open-label, repeat-dose escalation, safety and tolerability trial for patients with advanced hematological malignancies. STUDY COMPLETED.
BI-505 BI-505	BioInvent International (Sweden)	Dose escalation study of a monoclonal antibody to CD54. Study completed
BMS-833923 (XL139) BMS-833923 (XL139)	Bristol-Myers Squibb	Ascending dose study of BMS-833923 alone or in combination with lenalidomide plus dexamethasone or in combination with bortezomib in subjects with relapsed refractory mm
BMS-936564 (anti-CXCR4) BMS-936564 (anti-CXCR4)	Bristol-Myers Squibb	Open-label, multicenter study of (BMS-936564) in combination with lenalidomide (Revlimid) plus low-dose dexamethasone, or with bortezomib (Velcade) plus dexamethasone in subjects with relapsed or refractory MM.
Cometriq® cabozantinib XL 184 Cometriq® cabozantinib XL 184	Exelixis, Inc.	Dose-finding pilot study of cabozantinib (XL184) administered orally as monotherapy for the treatment of patients with relapsed or relapsed/refractory MM with bone disease.
CP-751,871 CP-751,871	Pfizer	Open-label study of CP-751,871 in patients with MM. Study completed.
CUDC-907 CUDC-907	Curis, Inc.	Phase I study to assess the safety, tolerability, and pharmacokinetics of CUDC-907 in patients with lymphoma and multiple myeloma.
CX-4945 CX-4945	Cylene Pharmaceuticals	Multi-center, open-label, dose-escalation, safety, pharmacokinetic and pharmacodynamic study; administered orally. Site contact: J. Shelby, RN, 970-212-7609, Front Range Cancer Specialists, Fort Collins, CO, PI Robert Marschke, MD
DFRF4539A DFRF4539A	Genentech Inc.	Open-label, multi-center trial of safety and pharmacokinetics of escalating doses of DFRF4539A in patients with relapsed or refractory MM
DKN-01 DKN-01	Dekkun Corporation	DKN-01 in MM or advanced solid tumors.
dovitinib TKI258 dovitinib TKI258	Novartis	Dovitinib combined with bortezomib and dexamethasone for relapsed/refractory MM. Not yet recruiting as of 9/6/12.
elotuzumab HuLuc63 elotuzumab HuLuc63	Bristol-Myers Squibb	study of elotuzumab in combination with lenalidomide and dexamethasone in subjects with MM and various levels of renal function
ENMD-2076 ENMD-2076	EntreMed	Oral selective kinase inhibitor currently in phase I for relapsed or refractory myeloma
Erivedge® vismodegib GDC-0449 Erivedge® vismodegib GDC-0449	NCI and Sidney Kimmel CCC; Genentech	Hedgehog pathway inhibitor used following autologous transplant in patients with high-risk first remission or relapsed MM.
fenretinide 4-HPR fenretinide 4-HPR	California Cancer Consortium; NCI	Intravenous chemotherapy agent in a safety and tolerability study for patients with relapsed or refractory hematologic cancer
flavopiridol; alvocidib HMR 1275, L86-8275 flavopiridol; alvocidib HMR 1275, L86-8275	NCI	Bortezomib and flavopiridol in treating patients with recurrent or refractory indolent B-cell neoplasms.
fluphenazine fluphenazine	Immune Control, Inc.	Serotonin antagonist for relapsed/refractory mm.
Folotyn® pralatrexate Folotyn® pralatrexate	Allos Therapeutics, Inc.	Approved for peripheral T-cell lymphoma, now in safety and dosing study in combination with Velcade for relapsed/refractory mm
ganetespib STA-9090 ganetespib STA-9090	Synta Pharmaceuticals	Ganetespib +/- bortezomib in patients with relapsed and/or refractory MM
GSK1120212 GSK1120212	GlaxoSmithKline	Open-label, 2-part study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the MEK Inhibitor GSK1120212 in combination with the AKT inhibitor GSK2110183 in subjects with solid tumors and MM. Active trial no longer recruiting patients.
GSK2110183 GSK2110183	GLaxoSmithKline	1) Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in MM subjects who have failed at least one line of systemic treatment. 2) See GSK1120212.
IPI-504 IPI-504	Infinity Pharmaceuticals	Safety and efficacy trial of Heat Shock Protein 90 inhibitor on patients with relapsed/refractory mm. Study completed.
ixazomib MLN9708 ixazomib MLN9708	Millennium: The Takeda Oncology Company	Several studies in progress with oral proteasome inhibitor for patients with newly diagnosed or relapsed/refractory MM.
KPT-330 KPT-330	NPM Pharma, Inc.	Safety study of the selective inhibitor of nuclear export (SINE) KPT-330 in patients with advanced hematological cancer.
KYPROLIS® carfilzomib PR-171 KYPROLIS® carfilzomib PR-171	Onyx Pharmaceuticals	Various trials with carfilzomib in combination with other drugs, including pomalidomide, ARRY-520.
LGH 447 LGH 447	Novartis	Orally bioavailable, small molecule pan-PIM kinase inhibitor for patients with relapsed and/or refractory MM.
lorvotuzumab mertansine BB-10901 (huN-901, IMGN901) lorvotuzumab mertansine BB-10901 (huN-901, IMGN901)	ImmunoGen, Inc.	Targets and kills cancer cells that express the CD 56 antigen. A humanized monoclonal antibody coupled with a cancer-killing agent.
lorvotuzumab mertansine IMGN901 (huN901-DM1/BB-10901) lorvotuzumab mertansine IMGN901 (huN901-DM1/BB-10901)	ImmunoGen, Inc.	In combination with Rev/dex in patients with relapsed/refractory MM.
marizomib (salinosporamide A) NPI-0052 marizomib (salinosporamide A) NPI-0052	Nereus Pharmaceuticals	Safety, pharmacokinetics, and pharmacodynamics of a novel, oral proteasome inhibitor in patients with rel/ref MM.
MFGR1877S MFGR1877S	Genentech Inc.	Open-label, multi-center trial of the safety and pharmacokinetics of escalating doses of a fully humanized monoclonal antibody to FGFR3 for patients with relapsed or refractory t(4;14)-positive MM. Study completed
MLN0128, INK128 MLN0128, INK128	Millennium Pharmaceuticals	Dose-escalation study of oral, small-molecule inhibitor of the TORC1 and TORC2 complexes in rel/ref mm and Waldenstrom's macroglobulinemia
MLN4924 MLN4924	Millennium Pharmaceuticals	Open-label, dose-escalation study of MLN4924, a novel inhibitor of Nedd8 activating enzyme, in adult patients with lymphoma or multiple myeloma Trial site locations: Winship Cancer Institute, Emory University, Atlanta, GA; U of Texas MD Anderson Cancer Center, Houston, TX
Nexavar® sorafenib, sorafenib tosylate BAY 43-9006, NSC-724772 Nexavar® sorafenib, sorafenib tosylate BAY 43-9006, NSC-724772	MD Anderson and Celgene	Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Plaquenil® hydroxychloroquine Plaquenil® hydroxychloroquine	OHSU Knight Cancer Institute	Cyclophosphamide, dexamethasone, rapamycin, hydroxychloroquine for relapsed/refractory MM.
Promacta® eltrombopag SB-497115-GR Promacta® eltrombopag SB-497115-GR	GlaxoSmithKline	Pilot study to evaluate the effect of eltrombopag plus G-CSF on human CD34+ cell mobilization and ex vivo colony proliferative capacity in patients with MM undergoing ASCT.
pyroxamide pyroxamide	National Cancer Institute	Histone deacytelase (HDAC) inhibitor for advanced malignancies.
radioimmunoimaging of AL amyloidosis 124I-labeled monoclonal antibody Mu 11-1F4 radioimmunoimaging of AL amyloidosis 124I-labeled monoclonal antibody Mu 11-1F4	University of Tennessee	To determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
Reolysin® wild-type reovirus Reolysin® wild-type reovirus	Oncolytics	Study of Reolysin alone in patients with relapsed or refractory MM.
reovirus, wild-type reovirus, wild-type	NCI	Study of the side effects and the best dose of giving viral therapy to patients with relapsed or refractory multiple myeloma. Viral therapy, such as wild-type reovirus, may be able to kill cancer cells without damaging normal cells
Revlimid® lenalidomide CC-5013 Revlimid® lenalidomide CC-5013	Celgene Corporation	Combined with various other drugs in relapsed/refractory MM.
rocilinostat ACY-1215 rocilinostat ACY-1215	Acetylon Pharmaceuticals	Open-label, multicenter study of ACY-1215 in combination with lenalidomide and dexamethasone for the treatment of relapsed or relapsed/refractory MM.
SAR650984 SAR650984	Sanofi	Anti-CD38 MAb in phase Ib trial to establish its MTD and dose-limiting toxicities in patients with relapsed or refractory MM.
SGN-40 SGN-40	Seattle Genetics, Genentech	Study in combination with Velcade in patients with rel/ref mm recruiting; study in combination with Rev/dex completed.
SNS-032 SNS-032	Sunesis	Dose-excalation study to examine the safety and tolerability, as well as preliminary anti-tumor activity, of a novel targeted inhibitor of CDKs 2, 7 and 9, in patients with B-cell malignancies.
SSST0001 SSST0001	Sigma-Tau Industrie Farmaceutiche Riunite SpA	Dose-finding study assessing safety and tolerability of SST0001 in advanced multiple myeloma.
TAK-901 TAK-901	Millennium Pharmaceuticals	Safety and tolerability study of an intravenous Aurora B kinase inhibitor for patients with advanced hematologic malignancies.
Torisel™ temsirolimus CCI-779 Torisel™ temsirolimus CCI-779	Wyeth	m-TOR inhibitor in combination with lenalidomide (Revlimid) for rel/ref MM.
VELCADE® bortezomib PS-341, LDP-341, MLN-341 VELCADE® bortezomib PS-341, LDP-341, MLN-341	Millennium: The Takeda Oncology Company	Trials combining VELCADE® with other agents in relapse setting.
veliparib ABT-888 veliparib ABT-888	Abbott	Veliparib (ABT-888) in combination with bortezomib and dexamethasone in patients with relapsed refractory MM.
veliparib ABT-888 veliparib ABT-888	Abbott	Study of ABT-888 in combination with bortezomib and dexamethasone in patients with relapsed refractory MM.
Vidaza® azacitidine Vidaza® azacitidine	Celgene Corporation	Various studies now recruiting MM patients, including in combination with Rev/dex and for patients with impaired renal function.
Viracept® nelfinavir mesylate Viracept® nelfinavir mesylate	Viiv Healthcare	Nelfinavir mesylate and bortezomib in treating patients with relapsed or progressive advanced hematologic cancer.
WT-1 vaccine WT-1 vaccine	Memorial Sloan-Kettering Cancer Center	Pilot trial of a Wilms Tumor analog peptide vaccine in patients with MM following ASCT.
Zarnestra™ tipifarnib FTI R115777, R115777 Zarnestra™ tipifarnib FTI R115777, R115777	Johnson & Johnson	Multi-center trial to determine optimal dosing of Velcade (bortezomib) in combination with Zarnestra (tipifarnib) for the treatment of relapsed/refractory mm.

Pre-Clinical

	COMPANY	INDICATION
1D09C3 1D09C3	GPC Biotech, AG	Fully human anti-HLA-DR antibody; its anti-mm activity is enhanced by IFN-gamma.
5AHQ (5-amino-8-hydroxyquinoline) 5AHQ (5-amino-8-hydroxyquinoline)	Princess Margaret Hospital	Novel chemical proteasome inhibitor induced cell death in 9/9 mm cell lines.
ABT-737 ABT-737	Abbott	Small molecule Bcl-2 inhibitor that also overcomes resistance to proteasome inhibition.
Actemra® tocilizumab injection Actemra® tocilizumab injection	Chugai Pharmaceutical Company; Hoffman-La Roche	Anti-human IL-6 receptor monoclonal antibody approved for treatment of Castleman’s Disease being studied in rheumatoid arthritis, Crohn’s Disease, and myeloma.
Ad-p53/GM-CSF/B7-1 immunotherapy Ad-p53/GM-CSF/B7-1 immunotherapy	Beijing Institute of Radiation Medicine	Recombinant adenovirus carrying human wild-type p53, granulocyte-macrophage colony-stimulating factor, and B7-1 genes.
AIN457 AIN457	Novartis	human monoclonal antibody targeting IL-17A that kills myeloma cells and inhibits osteoclasts
Alimta® pemetrexed Alimta® pemetrexed	Eli Lilly	FDA-approved antifolate chemo agent (for second-line therapy of non-small cell lung cancer) demonstrates potent anti-myeloma effect on cell lines and fresh cells from patients resistant to conventional agents
AMG523 AMG523	Amgen	B-cell activating factor (BAFF) inhibitor active in MM cell lines.
anti-beta2-microglobulin monoclonal antibodies (anti-B2M mAbs) anti-beta2-microglobulin monoclonal antibodies (anti-B2M mAbs)	MD Anderson Cancer Center	Strong apoptotic effect on myeloma cells suppports potential use as therapeutic agents.
anti-CD 32B monoclonal antibody anti-CD 32B monoclonal antibody	MacroGenics	Monoclonal antibody against low-affinity Fc receptor for use in the treatment of hematologic cancers.
anti-DKK1 anti-DKK1	UAMS	DKK1 neutralizing antibodies reduce osteolytic bone resorption, increase bone formation, and help control myeloma growth in lab mice.
antigen-loaded dendritic cell vaccine antigen-loaded dendritic cell vaccine	National Cancer Institute and Aastrom Biosciences	Idiotype vaccination following allogeneic transplant.
AP23841 AP23841	Ariad Pharmaceuticals	Small molecule inhibitor of osteoclasts.
apigenin apigenin		Common flavonoid that kills MM cells by targeting the trinity of CK2-Cdc37-Hsp90
APOMINE™ SR-45023A APOMINE™ SR-45023A	ILEX	Bisphosphonate ester.
AQX-MN100 AQX-MN100	Aquinox Pharmaceuticals	Sea sponge compound that inhibits immune and blood cell activation.
AT-101 AT-101	Ascenta Therapeutics, Inc.	Orally available pan-Bcl-2 inhibitor demonstrated significant anti-myeloma activity in vitro at Mayo Rochester.
ATL313 ATL313	CombinatoRx, Inc.	Adenosine A2A agonist compund used in combination therapy for the treatment of mm and other B-cell cancers.
AZD5363 AZD5363	AstraZeneca	Oral AKT inhibitor that shows activity in a wide range of cancers, including hematologic malignancies.
AZD8055 AZD8055	Astra Zeneca	novel selective mTOR kinase inhibitor
bafetinib INNO-406 bafetinib INNO-406	CytRx Corporation	orally available dual Bcr-Abl and Lyn kinase inhibitor that suppresses the activity of osteoclasts and inhibits bone resorption in cells from multiple myeloma patients
BAY 73-4056 BAY 73-4056	Bayer	Orally available multi-kinase inhibitor active in all MM cell lines.
berubicin berubicin		Mechanistically altered anthracycline analog.
BIO 5192 BIO 5192	Biogen	Small molecule inhibitor VLA-4 being studied for mobilization of hematopoietic stem cells
BiovaxID™ BiovaxID™	Biovest International/Accentia Biopharmaceuticals	Personalized, anti-idiotype vaccine for B-cell-related blood cancers.
BIRB 796 BIRB 796	Buchringer Ingelheim Pharmaceuticals	p38 MAPK inhibitor that overcomes drug resistance in the bone marrow microenvironment
bisphosphonate conjugates bisphosphonate conjugates	MBC Pharma	Compound drugs that couple a bisphosphonate with an anticancer agent to target bone and/or surrounding tissue.
BKM120 BKM120	Novartis	Oral pan-Class 1 P13K inhibitor already in phase 1 trials in solid tumors that induces apoptosis in MM cells and shows synergy with dexamethasone.
BLyS/rGel BLyS/rGel	Targa Therapeutics	Fusion protein of an antibody tethered to a toxin for the potential treatment of myeloma and autoimmune diseases.
BMS-214662 BMS-214662	Bristol-Myers Squibb	Farnesyltransferase inhibitor.
BP-1-102 BP-1-102	University of Toronto Lab	direct small-molecule inhibitor of stat3
C2-2b-2b C2-2b-2b	Immunomedics, Inc.	An immunocytokine comprising 4 molecules of interferon alpha-2b fused to the humanized antibody, IMMU-114, that targets the HLA-DR antigen.
C3B3 C3B3	Tokushima Graduate School of Medical Sciences	New diabody that induces cytotoxicity in both side population and main population myeloma cells.
CAL-101 CAL-101	Calistoga Pharmaceuticals	p110 delta-specific small molecule that triggers cytoxicity against mm cell lines and patient cells, but does not inhibit proliferation of normal peripheral blood mononuclear cells
capsaicin capsaicin	MD Anderson Cancer Center	Spicy component of hot pepper that preferentially induces apoptosis in MM cells. Low-dose combined capsaicin, thalidomide, and bortezomib triggered synergistic cytotoxicity.
cardamonin cardamonin	Huazhong U. of Science and Technology	Compound derived from plant used in traditional Chinese medicine that inhibits NF-kappa B and has anti-myeloma effects.
CCX721 CCX721	ChemoCentryx	Potent orally available inhibitor of CCR1 that is a suppressor of osteoclastic activity, osteolytic lesions, and disease burden in a preclinical MM mouse model.
CD32B Mab CD32B Mab	MacroGenics, Inc.	Monoclonal antibody targeted against CD32B; may have therapeutic potential in B-cell malignancies (NHL, CLL, MM).
CD74-DOX conjugate (anti-CD74 monoclonal antibody conjugated with doxorubicin) CD74-DOX conjugate (anti-CD74 monoclonal antibody conjugated with doxorubicin)	Immunomedics, Inc.	Therapy targeted to CD74-expressing MM cell lines.
CDDO-Im (CDDO-Imidazolide) CDDO-Im (CDDO-Imidazolide)	Johns-Hopkins and Dartmouth	A synthetic version of oleanolic acid, found in olive leaf extracts, which triggers apoptosis in mm cells.
CGEN-928 CGEN-928	Compugen Ltd.	Membrane protein that is expressed broadly on MM tumor cells and is has potential use as a drug target for MM.
chaetocin chaetocin	Mayo Clinic	A fungal toxin that demonstrates potent anti-myeloma activity through oxidative stress and consequent apoptosis induction.
ciclopirox olamine (CPX) off patent ciclopirox olamine (CPX) off patent		Prescription medication for fungal infections tested and found to have anti-myeloma and anti-leukemia activity.
cKap cKap	PacMab Ltd.	Chimeric version of the murine antibody, mKap, that induces apoptosis in all myeloma cell lines shown to express the surface antigen KMA. cKap is highly effective in inducing antigen-dependent cellular cytotoxicity.
Compound A (CA) Compound A (CA)		Pan-phosphatidylinositol 3-kinase (PI3K) inhibitor
CP-533,536 CP-533,536	Pfizer	Triggers healing of fractures and bone defects.
CPHPC CPHPC	Royal Free Hospital, London	Binds to serum amyloid P compound to prevent amyloid deposition.
CPS11 & CPS49 CPS11 & CPS49	Celgene Corporation	Thalidomide analogs developed at University of Leipzig and licensed to Celgene.
CR2408 CR2408	4SC AG	Novel pan-HDAC inhibitor with potent anti-myeloma effects.
CRB-15 (IL-15 cytokine receptor blocker) CRB-15 (IL-15 cytokine receptor blocker)	Roche, Cardion AG	Targeted against IL-15 receptor to prevent transplant rejection.
CYC065 CYC065	Cyclacel	derivative of seliciclib
cyclopamine; Hedgehog Pathway inhibitor IPI-926 cyclopamine; Hedgehog Pathway inhibitor IPI-926	Infinity Pharmaceuticals	Orally available derivative of cyclopamine inhibits the Hedgehog Pathway (which takes its name from an intercellular signaling molecule). Hedgehog pathway plays an important role in cancer stem cells.
CYT997 CYT997	Cytopia, Ltd.	novel tubulin polymerization inhibitor that synergizes with bortezomib for potent anti-MM activity.
degrasyn degrasyn	Callisto Pharmaceuticals	Small molecule that induces degradation of c-Myc in mm and other tumor cell lines.
derivative of seliciclib CYC065 derivative of seliciclib CYC065	Cyclacel	Oral cyclin dependent kinase inhibitor
dichloroacetate (DCA) dichloroacetate (DCA)		Chemical compound that induces selective killing of cancer cells by altering their metabolism.
DMAPT (dimethylamino- parthenolide) DMAPT (dimethylamino- parthenolide)	Indiana University	NFkB inhibitor demonstrated excellent efficacy in preclinical mouse models of mm alone and in combination with bortezomib and with lenolidomide.
DOM 1112 DOM 1112	Domantis	Dual targeting domain antibody (dAb) directed against CD38 and CD138 for the potential treatment of mm.
EGCG (epigallocatechin -3-gallate) EGCG (epigallocatechin -3-gallate)	Dana-Farber, VA Boston	Polyphenol extracted from green tea induces growth arrest and apoptosis in myeloma cells.
ENMD-981693 ENMD-981693	EntreMed	Oral, multi-target aurora kinase-angiogenesis inhibitor that demonstrates tumor regression and significant growth inhibition in mm xenografts
entinostat SNDX-275 entinostat SNDX-275	Syndax	HDAC inhibitor and bendamustine enhance each other's efficacy against MM cells.
Evista® raloxifene Evista® raloxifene	University of Liege	Selective estrogen receptor modulator that induces myeloma cell cycle arrest and apoptosis.
factor 5A (eukaryotic translation initiation factor 5A1) factor 5A (eukaryotic translation initiation factor 5A1)	Senesco Technologies, Inc.	Controls formation of proteins required for cell death.
flubendazole flubendazole	Janssen	Approved anti-parasitic (antihelmintic) drug with previously unrecognized preclinical activity in leukemia and myeloma.
fludelone (Flu) fludelone (Flu)	Memorial Sloan-Kettering Cancer Center	Synthetic epothilone that eradicates myeloma cells grafted in mice.
ganoderma ganoderma	Cedars-Sinai Medical Center; University Hospital, Freiburg	Mushroom extract with antiproliferative activity against leukemia, lymphoma, and myeloma.
GDC-0941 GDC-0941	Genentech Inc.	PI3K inhibitor with single-agent activity in MM cell lines and patient myeloma cells.
geldanamycin (GA) geldanamycin (GA)	National Cancer Institute	Inhibits proteins that protect cancer cells from effects of therapy.
GF-15 GF-15		Novel compound that disrupts myeloma cell division and triggers cell death by preventing centrosomal clustering.
GO-Y030, GO-Y078 GO-Y030, GO-Y078	Akita University, Japan	Novel curcumin analogs with more potency than curcumin as suppressors of mm cells.
halofuginone halofuginone	Dana-Farber Cancer Institute	Orally available synthetic derivative of quinazolinone alkaloid induces mm cell death and improves survival in mice.
highly purified hematopoietic stem cells (HSCs) highly purified hematopoietic stem cells (HSCs)	Cellerant Therapeutics, Inc.	Eliminates cancer cells and T-cells from HSCs used in transplant.
honokiol (HNK) honokiol (HNK)	Dana-Farber Cancer Institute	Traditionally used in Chinese and Japanese medicine and derived from magnolia; cytotoxic to myeloma cell lines.
HSP90i HSP90i	Novartis	Novel orally bioavailable heat shock protein 90 inhibitor that induces apoptosis and synergizes with bortezomib in human myeloma cells
imexon imexon	University of Arizona	Induces apoptosis, oxidative stress, and mitochondrial alterations in myeloma cells.
IMMU-110 IMMU-110	Immunomedics, Inc.	Humanized monoclonal antibody conjugated with doxorubicin and targeted to CD74 antigen.
IMMU-114 IMMU-114	Immunomedics, Inc.	anti-HLA-DR humanized monoclonal antibody that is toxic to cells of several hematologic malignancies, including mm
Inderal® InnoPran® Pronol® propranolol Inderal® InnoPran® Pronol® propranolol		Beta blocker found to cause cell death in MM cell lines.
indolinone BIBF 1000 indolinone BIBF 1000	Boehringer Ingelheim Pharma GmbH	Targeted kinase inhibitor that induces apoptosis in t(4;14)-positive cell lines.
INNO-206 INNO-206	CytRx Corporation	prodrug for doxorubicin that offers the possibility to achieve higher levels of active doxorubicin within tumor cells.
ISIS 345794 ISIS 345794	Isis Pharmaceuticals	Antisense drug targeting STAT-3
ispinesib ispinesib	Cytokinetics	Novel inhibitor of kinesin spindle protein (KSP) induces cell death in MM cells, and overcomes resistance to conventional drugs and novel agents.
JQ1 JQ1	Dana-Farber Cancer Institute	Small molecule that shuts down MYC, a protein that enhances cancer cell growth.
JS-K (JS-kappa) JS-K (JS-kappa)	Dana-Farber Cancer Institute	Prodrug designed to release nitric oxide that shows significant cytotoxicity in both conventional therapy-sensitive and -resistant MM cell lines.
KOS-2484 KOS-2484	Kosan Biosciences	Third-generation Hsp-90 inhibitor.
KPT-185 KPT-185	Karyopharm Therapeutics	Selective CRM-1 inhibitor.
KRN5500 KRN5500	Kirin Co Ltd.	Exerts anti-mm effects by impairing both mm cells and osteoclasts in mice.
KT-5720 KT-5720	Chaim Sheba Medical Center (Israel)	Reverses multidrug resistance in cells from patients with MM. Good candidate for combination therapy.
L-NAME (N-G-nitro-L- arginine methyl ester ) L-NAME (N-G-nitro-L- arginine methyl ester )	Kumamoto University (Japan)	Nitric oxide synthase inhibitor.
LBW242 LBW242	Novartis; Dana-Farber	A low molecular weight second mitochondria-derived activator of caspases (smac) that promotes apoptosis in myeloma cells resistant to conventional and bortezomib therapies.
LC161 LC161	Novartis	Novel inhibitor of apoptosis (IAP) inhibitor
lexatumumab HGS-ETR2 lexatumumab HGS-ETR2	Human Genome Sciences	monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
LS 104 LS 104	LymphoSign	Kinase inhibitor that is active in myeloma in vitro.
mAb, C11C1 mAb, C11C1	Temple University School of Medicine	Monoclonal antibody to kininogen may improve the efficacy of conventional mm treatment with minimal side effects.
mAb, ICAM-1 mAb, ICAM-1	Abiogen	Monoclonal antibody being evaluated in Italy for the potential treatment of myeloma.
MAL3-101 MAL3-101	University of Pittsburgh	Small molecule Hsp70 inhibitor that shows strong anti-myeloma effectsin vitro and in vivo, and synergy with bortezomib.
manumycin manumycin	University of Bari, Italy	A natural farnesyltransferase inhibitor prevents proliferation and induces apoptosis of mm cells.
methyljasmonate methyljasmonate	Dana-Farber Cancer Institute	Plant stress hormone that demonstrates synergy with bortezomib in vitro and in vivo.
MGCD0103 MGCD0103	MethylGlene Inc.	HDAC inhibitor active against myeloma cell lines in combination with interferon alpha.
MK-0457 MK-0457	Merck (VX-680)	Pan-aurora kinase inhibitor that synergistically potentiates Apo2L/Trail cytotoxicity in mm cells sensitive and resistant to bortezomib
MK2461 MK2461	Merck	novel c-Met inhibitor
MKC 204 MKC 204	MannKind Corporation	Inhibits enzyme IRE-1alpha and restores unfolded protein response (UPR) function, enabling apoptosis to occur.
MKC-3946 MKC-3946	MannKind Corporation	inhibitor of IRE1alpha endoribonuclease
MLN3897 (formerly AVE9897) MLN3897 (formerly AVE9897)	Millennium: The Takeda Oncology Company	Novel specific antagonist of chemokine receptor CCR1 for the treatment of osteolytic bone disease in myeloma.
MMF (mycophenolate mofetil) MMF (mycophenolate mofetil)	University of Maryland	IMP dehydrogenase inhibitor active against myeloma cells in vitro.
MUC1-2-VNTR MUC1-2-VNTR	Kunming Medical University	DNA vaccine designed to suppress tumor growth in a murine model of MM
MyelomaCide_ Y-90 MyelomaCide_ Y-90	Immunomedics, Inc.	Y-90-labeled antibody.
nifuroxazide nifuroxazide	Dana-Farber Cancer Institute	Potent inhibitor of STAT signaling; shows cytotoxicity against mm cells that rely on STAT3 for survival.
nocodazole nocodazole	University of Pittsburgh	Drug for intestinal worms inhibits cytokines necessary for myeloma cell growth and causes mm cell death in vitro.
NPI-1342 NPI-1342	Nereus Pharmaceuticals	Novel small molecule inhibitor of NF-kappB.
NVP-AUY922 NVP-AUY922	Novartis	Novel heat shock protein 90 inhibitor.
NVP-HSP990 NVP-HSP990	Novartis & Vernalis	Novel, orally bioavailable HSP inhibitor with profound activity agains myeloma cells.
NVP-LAQ824 NVP-LAQ824	Novartis	Histone deacetylase inhibitor.
NVP-LDE225 NVP-LDE225	Novartis	Novel hedgehog pathway inhibitor is cytotoxic to myeloma stem cells.
OncoPep vaccine OncoPep vaccine	OncoPep	Vaccine composed of myeloma-specific peptides designed for HLA type A2 patients with smoldering myeloma
P5091 P5091	Progenra	A small-molecule inhibitor of USP7, resulting in apoptosis in MM cells resistant to Velcade.
parthenolide (PTL) parthenolide (PTL)	Indiana University; Sapporo Medical University	Extract from feverfew that strongly induces apoptosis in MM cell lines
patupilone (epothilone B) EPO906 patupilone (epothilone B) EPO906	Novartis	A novel chemo agent that inhibits growth and survivial of myeloma cells,including those resistant to conventional chemo.
PD173074 PD173074	GlaxoSmithKline	Small molecule fibroblast growth factor receptor inhibitor that inhibits the growth of two t(4;14)-positive MM lines.
PHI 380 PHI 380	Parker Hughes Cancer Center	Phenylarsonic acid derivative that causes apoptotic death to cell lines of various cancers, including myeloma.
PIM2 inhibitor PIM2 inhibitor	Jasco Pharmaceuticals	PiM2 kinase inhibitor with selective potency against mm cell lines with the t(14;16) and t(4;14) translocations.
PKC412 PKC412	Novartis	Tyrosine kinase inhibitor that targets fibroblast growth factor.
PKF115-584 PKF115-584	Dana-Farber Cancer Institute	Small molecule that blocks the beta-catenin/TCF protein complex.
plinabulin NPI-2358 plinabulin NPI-2358	Nereus Pharmaceuticals	Novel vascular-disrupting agent (VDA) with anti-angiogenic and anti-tumor activity against mm cells, without significant toxicity in normal cells. Is already in a phase II trial in non-small cell lung cancer.
PPAR-gamma ligands (15d-PGJ2 and ciglitazone) PPAR-gamma ligands (15d-PGJ2 and ciglitazone)	University of Rochester	Antidiabetic therapies that induce MM cell apoptosis
PPP (picropodophyllin) PPP (picropodophyllin)	Vrije University of Brussels	Cyclolignan that inhibits IGF-1R tyrosine kinase and reduces proliferation and angiogenesis of MM cells.
PRO-001 PRO-001	Prochon Biotech Ltd.	Anti-FGFR3 neutralizing antibody that is cytotoxic to t(4;14)-positive MM cells.
PS 1145 PS 1145	Millennium: The Takeda Oncology Company	kappaB kinase (IKK) inhibitor.
quisinostat JNJ-26481585 quisinostat JNJ-26481585	Johnson and Johnson	HDAC inhibitor that reduces tumor load and paraprotein secretion and increases bone volume and trabecular number in combination with Velcade.
R-etodolac SDX-101 R-etodolac SDX-101	Salmedix	Single component of the anti-inflammatory drug etodolac; circumvents drug resistance in MM cell lines.
recombinant human Mannose-Binding Lectin (rhMBL) recombinant human Mannose-Binding Lectin (rhMBL)	Enzon	For the treatment of severe infections in patients with mm and others who are MBL deficient.
reveromycin ( RM-A) reveromycin ( RM-A)	Enzo Life Sciences, Inc.	small microbial metabolite that is an antiresorbtive agent
reversine [2-(4- Morpholinoanilino)-6- cyclohexylaminopurine] reversine [2-(4- Morpholinoanilino)-6- cyclohexylaminopurine]	Dana Farber Cancer Institute	Small molecule that may represent a distinct class of agents with therapeutic potential for specific subsets of MM.
RGB 286638 RGB 286638	GPC Biotech AG	Multi-targeted small molecule inhibitor induces cell death and prolongs survival in mouse model.
rhPDGF rhPDGF	BioMimetic Therapeutics	Recombinant protein for the treatment of osteonecrosis of the jaw.
ruxolitinib INC424 ruxolitinib INC424	Jakafi®	JAK inhibitor approved for the treatment of myelofibrosis now being tested on MM cell lines.
salirasib, farnesylthiosalicylic acid (FTS) salirasib, farnesylthiosalicylic acid (FTS)	Tel Aviv University	Ras inhibitor
Sarasar™ lonafarnib SCH66336 Sarasar™ lonafarnib SCH66336	Schering-Plough	Farnesyltransferase inhibitor (FTI)
SDX-308 SDX-308	Salmedix	More potent analog of the non-steroidal anti-inflammatory drug SDX-101 (R-etodolac); inhibits osteoclast formation and myeloma cell proliferation.
seliciclib CYC202, R-Roscovitine seliciclib CYC202, R-Roscovitine	Cyclacel	cyclin-dependent kinase inhibitor
SF1126 SF1126	Semafore Pharmaceuticals	PI3K inhibitor that was in a phase I clinical trial in 2009 as monotherapy now demonstrates efficacy in combination with Velcade in lab studies.
SIRT1720 SIRT1720	Dana-Farber Cancer Institute	small molecule activator of SIRT1 that is structurally distinct from resveratrol that induced MM cell apoptosis in a xenograft mouse model.
skeletally targeted proteasome inhibitors (bone-targeting nanocapsules) skeletally targeted proteasome inhibitors (bone-targeting nanocapsules)	US Department of Defense, Southwest Research Institute and UT Health Science Center	Targeting proteasome inhibitors to myeloma lesions in bone via nanocapsules.
SL-401 SL-401	Stemline Therapeutics, Inc.	Inhibits growth of MM cells by a novel mechanism of killing tumor-promoting plasmacytoid dendritic cells (pDCs) in the MM microenvironment.
SNX-2112 SNX-2112	Pfizer (which bought Serenex in March ‘08)	Orally available small molecule Hsp90 inhibitor that inhibits MM cell growth.
SRI16388 SRI16388	Stanford Research Institute	Orally available anti-angiogenic molecule that kills myeloma cells by blocking their ability to survive in a hypoxic microenvironment.
StemEx® StemEx®	Gamida Cell	Hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy.
STF-083010 STF-083010	Stanford University	Ire1 endonuclease inhibitor that demonstrates significant anti-myeloma activity in model human MM xenografts
SU5402 SU5402	Sugen	Fibroblast growth factor receptor inhibitor that inhibits the growth of two t(4;14)-positive MM lines.
TAS-117 TAS-117	Taiho Pharmaceutical Co.	Akt inhibitor blocks MM cell growth in vitro and in vivo and enhances cytotoxicity of other agents.
Tc-99m-MIBI (technecium-99m 2-methoxy- isobutylisonitrile) Tc-99m-MIBI (technecium-99m 2-methoxy- isobutylisonitrile)	Uludag University (Turkey)	Sensitive imaging (scanning) technique.
TEN 010 TEN 010	Tensha Therapeutics	Small molecule bromodomain inhibitor developed by Dr. Jay Bradner of Dana-Farber Cancer Institute.
terameprocol (TMP) EM-1421 terameprocol (TMP) EM-1421	Erimos Pharmaceuticals	Small molecule Inhibitor of Sp1 activity that is synergistic with lenalidomide in vivo
TG02 TG02	Tragara Pharmaceuticals	Oral kinase inhibitor that potently and consistently inhibits proliferation and survival of myeloma cell lines.
TG101209 TG101209	TargeGen Inc.	Novel JAK2 inhibitor with significant activity in vitro in mm. Associated with preferential cytotoxicity for CD45+ myeloma cells
thioredoxin antisense molecules thioredoxin antisense molecules	Lorus Therapeutics, Inc.	Reduces level of thioredoxin.
TRAIL-RlmAb TRAIL-RlmAb	Human Genome Sciences	Binds to TRAIL, a TNF. Cleared by FDA for Phase I trial.
treosulfan treosulfan	University of Muenchen	Alkylating agent.
trichostatin A (TSA) trichostatin A (TSA)	University of Maryland	Histone deacetylase inhibitor that sensitizes TRAIL-resistant myeloma cells to remove the obstacles to programmed cell death.
triciribine phosphate monohydrate, TCN-P VQD-002 triciribine phosphate monohydrate, TCN-P VQD-002	VioQuest Pharmaceuticals	Small molecule anticancer compound that inhibits AKT (protein kinase B)
tubacin (aggresome inhibitor) tubacin (aggresome inhibitor)	Dana-Farber Cancer Institute and Broad Institute of MIT	Blocks the function of histone deacetylase 6; used with bortezomib as an alternative protein disposal inhibitor
UCN-01 (7-hydroxystaurosporine) UCN-01 (7-hydroxystaurosporine)	Keryx Biopharmaceuticals	Novel multi-kinase inhibitor that shows activity against myeloma cells in combination with farnesyltransferase inhibitors or statins.
ULBP2-BB4 ULBP2-BB4	University Hospital Cologne	Novel recombinant bispecific protein that strongly activates primary NK cells.
VE465 VE465	Vertex/Merck	Aurora kinase inhibitor that is active in vitro against MM cell lines and/or primary MM tumor cells resistant to various anti-myeloma therapies.
VEL-0230 VEL-0230	Velcura Therapeutics, Inc.	New chemical entity that both inhibits osteoclastogenesis and promotes osteoblastogenesis.
VSV (Δ51)-NIS (recombinant vesicular stomatitis virus) VSV (Δ51)-NIS (recombinant vesicular stomatitis virus)	Mayo Clinic and Ottowa Health Research Institute	Novel radiovirotherapy combination with VSV(Δ51)-NIS plus iodide-131 that is effective in vitro and in vivo.
VX-944 VX-944	Vertex Pharmaceuticals licensed to Avalon Pharmaceuticals	Enzymatic, small molecule inhibitor of inosine monophosphate dehydrogenase that inhibits in vitro growth of human mm.
WP1130 WP1130	synthesized at MD Anderson CC	small molecule inhibitor of Usp9x deubiquitinase activity for progressive or drug-refractory MM
XAV-939 XAV-939	Rockefeller Institute	A small molecule tankyrase inhibitor that blocks the proteasome's activity.
XmAb5592 XmAb5592	Xencor, Inc.	Humanized, anti-HM1.24monoclonal antibody with potent anti-myeloma effects in vivo.